Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics)(Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics))

概要

基本信息

药物类型

基因疗法

别名

Leber congenital amaurosis gene therapy

靶点

RPE65

作用方式

刺激剂

作用机制

RPE65刺激剂(甲维酸异构水解酶刺激剂)、基因转移

治疗领域

遗传病与畸形眼部疾病其他疾病

在研适应症

莱伯先天性黑蒙

非在研适应症

2型利伯先天性黑朦症

原研机构

Beacon Therapeutics (USA), Inc.

在研机构

UMass Chan Medical School

非在研机构

Beacon Therapeutics (USA), Inc.

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

关联

1

项与 Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics) 相关的临床试验

NCT00749957

/ Completed临床1/2期

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing RPE65 (rAAV2-CB-hRPE65) in Patients With Leber Congenital Amaurosis Type 2

The purpose of the study is to evaluate the safety and efficacy of an adeno-associated virus vector expressing RPE65 in patients with Leber congenital amaurosis caused by mutations in the RPE65 gene.
Funding Source - FDA OOPD

开始日期2009-06-17

申办/合作机构

Beacon Therapeutics (USA), Inc.

[+2]

100 项与 Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics) 相关的临床结果

登录后查看更多信息

100 项与 Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics) 相关的转化医学

登录后查看更多信息

100 项与 Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics) 相关的专利（医药）

登录后查看更多信息

3

项与 Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics) 相关的文献（医药）

2024-06-18·Translational Vision Science & Technology

Perimacular Atrophy Following Voretigene Neparvovec-Rzyl Treatment in the Setting of Previous Contralateral Eye Treatment With a Different Viral Vector

Article

作者: Lauer, Andreas K ; Weleber, Richard G ; Ku, Cristy A ; Yang, Paul ; Bailey, Steven T ; Igelman, Austin D ; Duncan, Jacque L ; Huang, Samuel J ; Pennesi, Mark E

PurposeTo report on cases of unilateral perimacular atrophy after treatment with voretigene neparvovec-rzyl, in the setting of previous contralateral eye treatment with a different viral vector.DesignSingle-center, retrospective chart review.MethodsIn this case series, four patients between the ages of six and 11 years old with RPE65-related retinopathy were treated unilaterally with rAAV2-CB-hRPE65 as part of a gene augmentation clinical trial (NCT00749957). Six to 10 years later the contralateral eyes were treated with the Food and Drug Administration-approved drug, voretigene neparvovec-rzyl. Best-corrected visual acuity (BCVA), fundus photos, ocular coherence tomography, two-color dark-adapted perimetry, full field stimulus threshold testing (FST), and location of subretinal bleb and chorioretinal atrophy were evaluated.ResultsThree out of four patients showed unilateral perimacular atrophy after treatment with voretigene, ranging from five to 22 months after treatment. Areas of robust visual field improvement were followed by areas of chorioretinal atrophy. Despite perimacular changes, BCVA, FST, and subjective improvements in vision and nyctalopia were maintained. Perimacular atrophy was not observed in the first eye treated with the previous viral vector.ConclusionsWe observed areas of robust visual field improvement followed by perimacular atrophy in voretigene treated eyes, as compared to the initially treated contralateral eyes.Translational RelevanceCaution is advised when using two different viral vectors between eyes in gene therapy. This may become an important issue in the future with increasing gene therapy clinical trials for inherited retinal dystrophies.

2018-12-01·Human Gene Therapy

Results at 5 Years After Gene Therapy for RPE65-Deficient Retinal Dystrophy

Article

作者: Thean, Beverly ; Pennesi, Mark E. ; Flotte, Terence R. ; Chegarnov, Elvira ; Whitebirch, Chris ; Humphries, Margaret ; Stout, J. Timothy ; Chulay, Jeffrey D. ; Weleber, Richard G. ; Yang, Paul ; Beasley, Kathleen N.

Previously, results at 2 years after subretinal injection of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in eight adults and four children with retinal degeneration caused by RPE65 mutations were reported. Now, results at 5 years after treatment in 11 of these subjects are reported. Subjects received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of two dose levels, and were followed for 5 years after treatment. The primary safety outcomes were ocular and non-ocular adverse events. Efficacy outcomes included changes in best corrected visual acuity, static perimetry hill of vision measurements for the central 30° (V₃₀), and total (V_TOT) visual field and kinetic perimetry visual field area. The only adverse events reported during years 3, 4, and 5 were minor intercurrent illnesses. Pediatric subjects had improvement in visual acuity and static perimetry in the treated eye, sometimes with a smaller improvement in the untreated eye, during the first 2 years of the study that persisted during years 3-5, with no consistent changes in kinetic perimetry during the study. Most adult subjects had no consistent changes in visual acuity or static perimetry during the study. Three adult subjects with markedly abnormal baseline kinetic visual field area had improvement in the treated eye during the first 1-2 years after treatment, but the absolute magnitude of the improvement was small and was not sustained at subsequent visits. There were no clinically significant adverse events. Visual acuity and static perimetry testing results suggest that treating patients at a younger age is associated with better visual function outcomes during 5 years after treatment.

2016-07-01·Ophthalmology1区 · 医学

Results at 2 Years after Gene Therapy for RPE65-Deficient Leber Congenital Amaurosis and Severe Early-Childhood–Onset Retinal Dystrophy

1区 · 医学

Article

作者: Humphries, Margaret ; Hauswirth, William W ; Kaushal, Shalesh ; Jensen, Lauren ; Calcedo, Roberto ; Erker, Laura R ; McBride, Maureen T ; Flotte, Terence R ; Chulay, Jeffrey D ; Stout, J Timothy ; Pennesi, Mark E ; Wilson, David J ; Weleber, Richard G

PURPOSETo provide an initial assessment of the safety of a recombinant adeno-associated virus vector expressing RPE65 (rAAV2-CB-hRPE65) in adults and children with retinal degeneration caused by RPE65 mutations.DESIGNNonrandomized, multicenter clinical trial.PARTICIPANTSEight adults and 4 children, 6 to 39 years of age, with Leber congenital amaurosis (LCA) or severe early-childhood-onset retinal degeneration (SECORD).METHODSPatients received a subretinal injection of rAAV2-CB-hRPE65 in the poorer-seeing eye, at either of 2 dose levels, and were followed up for 2 years after treatment.MAIN OUTCOME MEASURESThe primary safety measures were ocular and nonocular adverse events. Exploratory efficacy measures included changes in best-corrected visual acuity (BCVA), static perimetry central 30° visual field hill of vision (V30) and total visual field hill of vision (VTOT), kinetic perimetry visual field area, and responses to a quality-of-life questionnaire.RESULTSAll patients tolerated subretinal injections and there were no treatment-related serious adverse events. Common adverse events were those associated with the surgical procedure and included subconjunctival hemorrhage in 8 patients and ocular hyperemia in 5 patients. In the treated eye, BCVA increased in 5 patients, V30 increased in 6 patients, VTOT increased in 5 patients, and kinetic visual field area improved in 3 patients. One subject showed a decrease in BCVA and 2 patients showed a decrease in kinetic visual field area.CONCLUSIONSTreatment with rAAV2-CB-hRPE65 was not associated with serious adverse events, and improvement in 1 or more measures of visual function was observed in 9 of 12 patients. The greatest improvements in visual acuity were observed in younger patients with better baseline visual acuity. Evaluation of more patients and a longer duration of follow-up will be needed to determine the rate of uncommon or rare side effects or safety concerns.

100 项与 Leber congenital amaurosis gene therapy - Applied Genetic Technologies Corporation(Beacon Therapeutics) 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
莱伯先天性黑蒙	临床2期	-	UMass Chan Medical School	-
2型利伯先天性黑朦症	临床1期	美国	Beacon Therapeutics (USA), Inc.	2009-06-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT00749957 (CTgov)	临床1/2期	2型利伯先天性黑朦症	12	rAAV2-CB-hRPE65 (Lower Dose of rAAV2-CB-hRPE65)	願淵蓋艱糧鏇網餘觸鏇(構願網醖窪齋選築遞鬱) = 觸齋鹹鹽遞遞獵範鑰築夢鹽鑰糧網憲積窪糧構 (艱衊鏇選窪觸餘繭膚範, 憲糧醖襯願窪艱製鏇膚 ~ 願鬱積鬱廠窪蓋願築築) 更多	-	2016-04-08
NCT00749957 (CTgov)	临床1/2期	2型利伯先天性黑朦症	12	rAAV2-CB-hRPE65 (Higher Dose of rAAV2-CB-hRPE65)	願淵蓋艱糧鏇網餘觸鏇(構願網醖窪齋選築遞鬱) = 願範願艱遞製鹽築鑰醖夢鹽鑰糧網憲積窪糧構 (艱衊鏇選窪觸餘繭膚範, 觸鑰鹹憲願範餘築壓艱 ~ 齋襯艱餘壓壓繭憲淵網) 更多	-	2016-04-08
ARVO2013	N/A	2型利伯先天性黑朦症 RPE65 mutations	12	AAV Vector Expressing RPE65rAAV2-CB-hRPE65essing RPE65 (rAAV2-CB-hRPE65)	(鹽鬱願繭齋選獵齋鬱製) = 觸鬱範選壓鹹齋餘選淵鏇壓衊鹹觸簾糧襯獵築 (蓋選齋範廠窪遞選淵艱 ) 更多	积极	2013-06-01